Literature DB >> 24346238

Mental disturbances in Parkinson's disease and related disorders: the role of excitotoxins.

Izabella Obál1, Zsófia Majláth1, József Toldi2, László Vécsei3.   

Abstract

The pathomechanism behind the neurodegenerative process in Parkinson's disease involves damage to the dopaminergic and nondopaminergic systems with dysfunctioning of the dopaminergic-glutamatergic circuitry in the basal ganglional neural processing. Excitotoxicity may contribute markedly to neuronal damage and loss. Beside the cardinal motor signs of the disease, non-motor symptoms, including mental disturbances, are characteristic features of the clinical course. Affective or autonomic changes may precede motor symptoms. Neuroprotective drugs are not yet available. However, new modes of therapy targeting the defective dopaminergic-glutamatergic system might also be effective both for symptomatologic treatment and for neuroprotection. Alterations in the kynurenine pathway have been demonstrated in Parkinson's disease. Preclinical studies suggest that intervention in the kynurenine pathway may result in neuroprotection and additionally alleviate the symptoms through influencing the glutamatergic neurotransmission.

Entities:  

Keywords:  Parkinson's disease; dopaminergic dysfunction; excitotoxicity; kynurenine pathway; mental disturbances; neuroprotection; non-motor symptoms

Mesh:

Substances:

Year:  2014        PMID: 24346238     DOI: 10.3233/JPD-130294

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN: 1877-7171            Impact factor:   5.568


  5 in total

Review 1.  Parkinson's disease: Microglial/macrophage-induced immunoexcitotoxicity as a central mechanism of neurodegeneration.

Authors:  Russell L Blaylock
Journal:  Surg Neurol Int       Date:  2017-04-26

Review 2.  Spotlight on opicapone as an adjunct to levodopa in Parkinson's disease: design, development and potential place in therapy.

Authors:  Ádám Annus; László Vécsei
Journal:  Drug Des Devel Ther       Date:  2017-01-09       Impact factor: 4.162

Review 3.  Are Kynurenines Accomplices or Principal Villains in Dementia? Maintenance of Kynurenine Metabolism.

Authors:  Masaru Tanaka; Zsuzsanna Bohár; László Vécsei
Journal:  Molecules       Date:  2020-01-28       Impact factor: 4.411

4.  Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.

Authors:  Mobina Fathi; Kimia Vakili; Shirin Yaghoobpoor; Arian Tavasol; Kimia Jazi; Ramtin Hajibeygi; Sina Shool; Fatemeh Sodeifian; Andis Klegeris; Alyssa McElhinney; Mostafa Rezaei Tavirani; Fatemeh Sayehmiri
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786

5.  Potential Therapeutic Drugs for Parkinson's Disease Based on Data Mining and Bioinformatics Analysis.

Authors:  Chuan Xu; Jiajun Chen; Xia Xu; Yingyu Zhang; Jia Li
Journal:  Parkinsons Dis       Date:  2018-10-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.